jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/
Company profile
Ticker
JAGX
Exchange
Website
CEO
Lisa Conte
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Jaguar Animal Health, Inc.
SEC CIK
Corporate docs
Subsidiaries
Napo Pharmaceuticals, Inc. ...
JAGX stock data
Latest filings (excl ownership)
S-3
Shelf registration
22 Apr 24
10-K/A
2023 FY
Annual report (amended)
17 Apr 24
8-K
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
9 Apr 24
424B5
Prospectus supplement for primary offering
2 Apr 24
S-8
Registration of securities for employees
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory
21 Mar 24
DEF 14A
Definitive proxy
15 Mar 24
8-K
Unregistered Sales of Equity Securities
8 Mar 24
PRE 14A
Preliminary proxy
5 Mar 24
Transcripts
JAGX
Earnings call transcript
2023 Q4
1 Apr 24
JAGX
Earnings call transcript
2023 Q3
14 Nov 23
JAGX
Earnings call transcript
2023 Q2
14 Aug 23
JAGX
Earnings call transcript
2023 Q1
15 May 23
JAGX
Earnings call transcript
2022 Q4
27 Mar 23
JAGX
Earnings call transcript
2022 Q3
14 Nov 22
JAGX
Earnings call transcript
2022 Q2
22 Aug 22
JAGX
Earnings call transcript
2022 Q1
10 May 22
JAGX
Earnings call transcript
2021 Q4
14 Mar 22
JAGX
Earnings call transcript
2021 Q3
17 Nov 21
Latest ownership filings
4
Pravin R Chaturvedi
17 Apr 24
4
Jonathan S. Wolin
17 Apr 24
4
Carol R. Lizak
17 Apr 24
4
Steven R. King
17 Apr 24
4
LISA A CONTE
17 Apr 24
SC 13G
Iliad Research & Trading, L.P.
29 Dec 23
4
Anula Jayasuriya
14 Aug 23
4
Jonathan B. Siegel
14 Aug 23
4
JOHN MICEK
14 Aug 23
4
JAMES J BOCHNOWSKI
14 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.23 mm | 3.23 mm | 3.23 mm | 3.23 mm | 3.23 mm | 3.23 mm |
Cash burn (monthly) | 1.80 mm | 611.25 k | 2.93 mm | 3.48 mm | 2.26 mm | 2.68 mm |
Cash used (since last report) | 12.28 mm | 4.17 mm | 19.98 mm | 23.71 mm | 15.44 mm | 18.31 mm |
Cash remaining | -9.06 mm | -944.14 k | -16.76 mm | -20.49 mm | -12.22 mm | -15.09 mm |
Runway (months of cash) | -5.0 | -1.5 | -5.7 | -5.9 | -5.4 | -5.6 |
Institutional ownership, Q3 2023
17.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 1 |
Closed positions | 3 |
Increased positions | 5 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 3.30 bn |
Total shares | 49.44 mm |
Total puts | 0.00 |
Total calls | 17.90 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Nantucket Investments | 23.63 mm | $3.15 bn |
Streeterville Capital | 11.50 mm | $0.00 |
Iliad Research & Trading | 4.75 mm | $930.00 k |
Oasis Capital | 4.60 mm | $0.00 |
Mailman Joshua | 4.37 mm | $0.00 |
Vanguard | 192.34 k | $50.01 mm |
Geode Capital Management | 92.33 k | $24.01 mm |
JPM JPMorgan Chase & Co. | 85.38 k | $22.20 mm |
BLK Blackrock | 51.16 k | $13.30 mm |
MS Morgan Stanley | 49.09 k | $12.76 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Apr 24 | Conte Lisa A | Common Stock | Option exercise | Acquire M | No | No | 0 | 600 | 0.00 | 4,600 |
5 Apr 24 | Conte Lisa A | RSU Common Stock | Grant | Dispose A | No | No | 0 | 600 | 0.00 | 0 |
5 Apr 24 | Lizak Carol R. | Common Stock | Option exercise | Acquire M | No | No | 0 | 60 | 0.00 | 611 |
5 Apr 24 | Lizak Carol R. | RSU Common Stock | Grant | Dispose A | No | No | 0 | 60 | 0.00 | 0 |
5 Apr 24 | Wolin Jonathan S. | Common Stock | Option exercise | Acquire M | No | No | 0 | 89 | 0.00 | 1,141 |
5 Apr 24 | Wolin Jonathan S. | RSU Common Stock | Grant | Dispose A | No | No | 0 | 89 | 0.00 | 0 |
5 Apr 24 | King Steven R. | Common Stock | Option exercise | Acquire M | No | No | 0 | 178 | 0.00 | 1,144 |
5 Apr 24 | King Steven R. | RSU Common Stock | Grant | Dispose A | No | No | 0 | 178 | 0.00 | 0 |
5 Apr 24 | Pravin R Chaturvedi | Common Stock | Option exercise | Acquire M | No | No | 0 | 134 | 0.00 | 1,270 |
5 Apr 24 | Pravin R Chaturvedi | RSU Common Stock | Grant | Dispose A | No | No | 0 | 134 | 0.00 | 0 |
News
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
23 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
23 Apr 24
Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
23 Apr 24
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
22 Apr 24
S&P 500 Edges Lower; PacBio Shares Plunge
16 Apr 24
Press releases
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care
22 Apr 24
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
18 Apr 24
Exploring Stock Surges: Key Insights, Noteworthy BUZZ: KAVL, PRSO, DYAI, WISA, JAGX
16 Apr 24
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
16 Apr 24
Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
9 Apr 24